EZ Cap™ EGFP mRNA (5-moUTP)
EZ Cap™ EGFP mRNA (5-moUTP) will express enhanced green fluorescent protein(EGFP) once entering cells originally isolated from the jellyfish(Aequorea victoria). You can observe the green fluorescence at 509 nm. EGFP is usually used as a reporter for gene regulation and function study. It is applicable in assays for mRNA delivery, translation efficiency, cell viability and in vivo imaging etc.
Key features:
Cap1 Structure: The mRNA incorporates a Cap1 analog at the 5' end, ensuring high translation initiation efficiency, improved stability, and reduced innate immune recognition, leading to stronger and more sustained luciferase expression.
Modified Nucleotides: It contains 5-methoxyuridine (5-moU) modified nucleotides, which decreases immunogenicity, enhances mRNA stability, and increases translational efficiency, resulting in more reliable and reproducible protein yield.
poly(A) tail: It contains an optimized poly(A) tail of approximately 100 nucleotides. This specific length is engineered to maximize transcript stability by resisting degradation and to synergize with the 5' cap for superior, sustained translation efficiency, ensuring robust protein yield in your applications.
| mRNA Length | 996 nucleotides | ||
| Concentration | 1 mg/mL | ||
| Buffer | 1 mM Sodium Citrate, pH 6.4 | Storage | -40°C or below |
| General tips | Please dissolve it on ice and protect from RNase carefully. Avoid repeated freeze/thaw cycles as possible. Don’t vortex. Upon first use, centrifuge the tube softly and aliquot it into several single use portions. Use RNase-free reagents and materials with appropriate RNase-free technique. Don’t add to the media with serum unless mixing with a transfection reagent. | ||
| Shipping Condition | ship with dry ice. | ||
- 1. Shuling Ren, Xinyu Lin, et al. "Redox-Responsive Peptide Coacervates for Enhanced mRNA Delivery and Intracellular Release." ACS Nano. 2025 Dec 26. PMID: 41451635
- 2. Xu Ma, Shaoli Liu, et al. "Engineering of mRNA vaccine platform with reduced lipids and enhanced efficacy." Nat Commun. 2025 Oct 7;16(1):8913. PMID: 41057328
- 3. Zhenghua Li, Jiacai Wu, et al. "mRNA-LNP hydrogels promote skeletal muscle regeneration in situ." Journal of Controlled Release Available online 23 September 2025, 114258. PMID: 40997951
- 4. Desheng Cao, Junliang Zhu, et al. "Dynamically covalent lipid nanoparticles mediate CRISPR-Cas9 genome editing against choroidal neovascularization in mice." Sci Adv. 2025 Jul 11;11(28):eadj0006. PMID: 40644543
- 5. Christopher J LaSalle, David V Morrissey, et al. "Clickable and Degradable Polycarbonate Vehicles for mRNA Delivery." Bioconjug Chem. 2025 Jul 9. PMID: 40633113
- 6. Susana Farinha, Rute Mota, et al. "Mitigating Shear Stress in Spray Drying for RNA - Loaded Lipid Nanoparticles through Process and Formulation Optimization." AAPS PharmSciTech. 2025 May 28;26(5):145. PMID: 40437126
- 7. Siyu Dong, Zhaoqi Pan, et al. "Lipid Nanoparticles - Mediated mRNA Delivery to the Eye Affected by Ionizable Cationic Lipid." Mol Pharm. 2025 Jun 2;22(6):3297-3307. PMID: 40331524
- 8. Xueying Tang, Jiashuo Zhang, et al. "Autonomic lysosomal escape via sialic acid modification enhances mRNA lipid nanoparticles to eradicate tumors and build humoral immune memory." J Control Release. 2025 Jun 10:382:113647. PMID: 40158813
- 9. Chunyan Fu, Xiaoqin Jin, et al. "Macrophage-targeted Mms6 mRNA-lipid nanoparticles promote locomotor functional recovery after traumatic spinal cord injury in mice." Sci Adv. 2025 Mar 28;11(13):eads2295. PMID: 40138430
- 10. Mehrnoosh Rafiei, Akbar Shojaei, et al. "Machine learning-assisted design of immunomodulatory lipid nanoparticles for delivery of mRNA to repolarize hyperactivated microglia." Drug Deliv. 2025 Dec;32(1):2465909. PMID: 40028722
- 11. Chuanmei Tang, Yexi Zhang, et al. "Modular Design of Lipopeptide‐Based Organ‐Specific Targeting (POST) Lipid Nanoparticles for Highly Efficient RNA Delivery." Adv Mater.2025 Mar;37(11):e2415643. PMID: 39924757
- 12. Tian He, Yating Li, et al. "Enhanced Antitumor Efficacy of STING Agonist MSA-2 by Lipid Nanoparticles Delivering Circular IL-23 mRNA and Platinum-Modified MSA-2 Combination." Mater Today Bio. 2025 Jan 3:30:101446. PMID: 39866787
- 13. Bhanubhong Prommalee, Chalermchai Pilapong. "The development of a milk-derived nanovesicle with its potentials for nucleic acid delivery and bioconjugation." Nanotheranostics 2025; 9(3): 280-288.
- 14. Chenzhen Zhang, Tanvi V. Pathrikar, et al. "Charge‐reversed exosomes for targeted gene delivery to cartilage for osteoarthritis treatment." Small Methods. 2024 Sep;8(9):e2301443. PMID: 38607953
- 15. Xueying Tang, et al. "Durable protective efficiency provide by mRNA vaccines require robust immune memory to antigens and weak immune memory to lipid nanoparticles." Mater Today Bio. 2024 Feb 9:25:100988. PMID: 38379935
- 16. Yixuan Huang, Jiacai Wu, et al. "Quaternization drives spleen-to-lung tropism conversion for mRNA-loaded lipid-like nanoassemblies." Theranostics. 2024 Jan 1;14(2):830-842. PMID: 38169552
- 17. Franziska Haase, geb. Freitag aus Düsseldorf, Deutschland. "A novel class of mRNA lipid nanoparticles (LNPs) optimized by the chemical evolution approach." 2024
- 18. Mingzhu Gao, Maoping Tang, et al. "Modulating Plaque Inflammation via Targeted mRNA Nanoparticles for the Treatment of Atherosclerosis." ACS Nano. 2023 Sep 26;17(18):17721-17739. PMID: 37669404
- 19. Min Li, Yixuan Huang, et al. "A PEG-lipid-free COVID-19 mRNA vaccine triggers robust immune responses in mice." Mater Horiz. 2023 Feb 6;10(2):466-472. PMID: 36468425
- 20. Y. Huang, M. Yang, et al. "Intracellular delivery of messenger RNA to macrophages with surfactant-derived lipid nanoparticles." Materials Today Advances Volume 16, December 2022, 100295
Quality Control & Datasheet
- View current batch:
Related Biological Data

Related Biological Data

Related Biological Data

It can be based on your experimental goals:
- For Tracking Transfection and Translation Efficiency: APExBIO Reporter Gene mRNAs (e.g. EGFP, Firefly Luciferase mRNA) are commonly used to track transfection efficiency and protein expression duration; evaluate gene expression and cell viability; study mRNA localization and bio-distribution via in vivo imaging; optimize transfection conditions and validate LNP delivery system.
- For Gene Editing, Functional Studies and Gene Therapy Research: APExBIO offers various functional protein mRNAs, involving tumor suppressors (e.g. p53, PTEN), cytokines (e.g. IL-12, IL-10), gene-editing tools (e.g. spCas9, Cre Recombinase), gene replacement protein (e.g. EPO), and antigens (e.g. OVA, SARS-CoV-2 Spike).
- For Sustained Protein Expression: APExBIO Self-amplifying RNA (saRNA) and Circular RNA (circRNA) are recommended for applications requiring prolonged protein expression. saRNA enables lasting and strong protein expression at lower doses, while circRNA has enhanced structural stability and extended expression duration.
- Advanced Capping Technology: Utilizes Cap 1 structure (EZ Cap™ Cap) to achieve enhanced translation efficiency and minimizing activation of the host innate immune response. The capping efficiency can reach 90–99%.
- Diverse Modification Options: Provides a range of modified nucleotides, such as m1Ψ B8049, 5-moUTP B8061 and Cy5-UTP B8333, which reduce immunogenicity, improve mRNA stability, and maximize protein expression levels.
- Stringent Quality Control: Each batch undergoes rigorous quality assessment including capping efficiency, purity, integrity, and sterility to ensure batch-to-batch consistency.























